74 related articles for article (PubMed ID: 24894093)
41. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
[TBL] [Abstract][Full Text] [Related]
42. Postoperative bronchopulmonary complications in stage III lung cancer patients treated with preoperative paclitaxel-containing chemotherapy and concurrent radiation.
Bonomi P; Faber LP; Warren W; Lincoln S; LaFollette S; Sharma M; Recine D
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-123-S12-129. PubMed ID: 9331136
[TBL] [Abstract][Full Text] [Related]
43. Temporal interactions in the Lewis lung tumour between cytotoxic drugs and acute or fractionated radiotherapy.
Stephens TC; Adams K; Peacock JH; Steel GG
Radiother Oncol; 1986 Feb; 5(2):137-46. PubMed ID: 3704188
[TBL] [Abstract][Full Text] [Related]
44. Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases.
Kamata M; Denda-Nagai K; Kubota N; Aida S; Takeda K; Irimura T
Clin Exp Metastasis; 2002; 19(8):689-96. PubMed ID: 12553374
[TBL] [Abstract][Full Text] [Related]
45. Animal experiments on the role of T lymphocytes in the course of antineoplastic chemotherapy. II. Chemotherapy and T lymphocyte depression.
Bier H
ORL J Otorhinolaryngol Relat Spec; 1987; 49(2):57-66. PubMed ID: 3496572
[TBL] [Abstract][Full Text] [Related]
46. Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy.
Kao CJ; Wurz GT; Schröder A; Wolf M; Degregorio MW
Oncoimmunology; 2013 Oct; 2(10):e26285. PubMed ID: 24498545
[TBL] [Abstract][Full Text] [Related]
47. Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients?
Wauters E; Vansteenkiste J
J Thorac Dis; 2014 Jun; 6(6):574-7. PubMed ID: 24976973
[No Abstract] [Full Text] [Related]
48. Assessing the Effects of Concurrent versus Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 Mice.
Kao CJ; Wurz GT; Lin YC; Vang DP; Griffey SM; Wolf M; DeGregorio MW
Cancer Immunol Res; 2015 Jul; 3(7):741-50. PubMed ID: 25672395
[TBL] [Abstract][Full Text] [Related]
49. Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer.
Xiao R; Allen CT; Tran L; Patel P; Park SJ; Chen Z; Van Waes C; Schmitt NC
Oncoimmunology; 2018; 7(9):e1471440. PubMed ID: 30393585
[TBL] [Abstract][Full Text] [Related]
50. Cytokines and radiation-induced pulmonary injuries.
Lierova A; Jelicova M; Nemcova M; Proksova M; Pejchal J; Zarybnicka L; Sinkorova Z
J Radiat Res; 2018 Nov; 59(6):709-753. PubMed ID: 30169853
[TBL] [Abstract][Full Text] [Related]
51. MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer.
Gunda V; Souchek J; Abrego J; Shukla SK; Goode GD; Vernucci E; Dasgupta A; Chaika NV; King RJ; Li S; Wang S; Yu F; Bessho T; Lin C; Singh PK
Clin Cancer Res; 2017 Oct; 23(19):5881-5891. PubMed ID: 28720669
[No Abstract] [Full Text] [Related]
52. Muc1 knockout potentiates murine lung carcinogenesis involving an epiregulin-mediated EGFR activation feedback loop.
Xu X; Chen W; Leng S; Padilla MT; Saxton B; Hutt J; Tessema M; Kato K; Kim KC; Belinsky SA; Lin Y
Carcinogenesis; 2017 Jun; 38(6):604-614. PubMed ID: 28472347
[TBL] [Abstract][Full Text] [Related]
53. Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy.
Yue T; Zheng X; Dou Y; Zheng X; Sun R; Tian Z; Wei H
BMC Cancer; 2016 Aug; 16(1):665. PubMed ID: 27549240
[TBL] [Abstract][Full Text] [Related]
54. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.
Wurz GT; Kao CJ; DeGregorio MW
Ther Adv Med Oncol; 2016 Jan; 8(1):4-31. PubMed ID: 26753003
[TBL] [Abstract][Full Text] [Related]
55. Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.
Mayor M; Yang N; Sterman D; Jones DR; Adusumilli PS
Eur J Cardiothorac Surg; 2016 May; 49(5):1324-33. PubMed ID: 26516195
[TBL] [Abstract][Full Text] [Related]
56. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
57. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial.
DeGregorio M; Soe L; Wolf M
J Thorac Dis; 2014 Jun; 6(6):571-3. PubMed ID: 24976972
[No Abstract] [Full Text] [Related]
58. Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model.
Kao CJ; Wurz GT; Monjazeb AM; Vang DP; Cadman TB; Griffey SM; Wolf M; DeGregorio MW
Cancer Immunol Res; 2014 Jun; 2(6):581-9. PubMed ID: 24894093
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
